These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 24449211

  • 1. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
    Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB, van den Bos C, Kollen WJ, Hop WC, Lanvers-Kaminsky C, Relling MV, Tissing WJ, van der Sluis IM.
    Blood; 2014 Mar 27; 123(13):2026-33. PubMed ID: 24449211
    [Abstract] [Full Text] [Related]

  • 2. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
    Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM.
    J Clin Oncol; 2020 Mar 01; 38(7):715-724. PubMed ID: 31922920
    [Abstract] [Full Text] [Related]

  • 3. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
    Tong WH, Pieters R, de Groot-Kruseman HA, Hop WC, Boos J, Tissing WJ, van der Sluis IM.
    Haematologica; 2014 Nov 01; 99(11):1716-21. PubMed ID: 25150254
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, Hak LJ.
    Leukemia; 2003 Aug 01; 17(8):1583-8. PubMed ID: 12886246
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM, Kirov II, Dreyer ZE, Kelly M, Hijiya N, Brown P, Drachtman RA, Messinger YH, Ritchey AK, Hale GA, Maloney K, Lu Y, Plourde PV, Silverman LB.
    Pediatr Blood Cancer; 2016 Feb 01; 63(2):228-33. PubMed ID: 26376459
    [Abstract] [Full Text] [Related]

  • 17. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
    Hak LJ, Relling MV, Cheng C, Pei D, Wang B, Sandlund JT, Rubnitz J, Pui CH.
    Leukemia; 2004 Jun 01; 18(6):1072-7. PubMed ID: 15057247
    [Abstract] [Full Text] [Related]

  • 18. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM.
    BioDrugs; 2013 Aug 01; 27(4):413-8. PubMed ID: 23794007
    [Abstract] [Full Text] [Related]

  • 19. Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia.
    Tong WH, Mesegué M, Dapena JL, Camós M, Rives S.
    Hematol Oncol; 2022 Oct 01; 40(4):809-811. PubMed ID: 34961954
    [No Abstract] [Full Text] [Related]

  • 20. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R.
    Oncologist; 2007 Aug 01; 12(8):991-8. PubMed ID: 17766659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.